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Introduction
Immune–mediated (type 1) diabetes (IMD) is an incur-
able disease of children and adults that is increasing in
incidence throughout the Western world (1). It results
from chronic autoimmune destruction of pancreatic β
cells in individuals who are genetically prone to IMD
through having multiple weak susceptibility genes in
the absence of protective genes, with penetrances that
are strongly influenced by the environment. The dis-
covery of Th1 and Th2 subsets has helped to explain
the immunological basis for the diversity of T cell
responses in autoimmune diseases such as IMD (2).
Destruction of pancreatic β cells in humans and
nonobese diabetic (NOD) mice is mediated through
cellular immune mechanisms and a biased Th1
immune pathway. Various studies in NOD mice have
shown that β cell destruction is observed in conjunc-
tion with infiltration of local IFN-γ+ T cells (3), while
experimentally induced lesions dominated by IL-4–pro-
ducing T cells are generally benign to or even protect
against islet cell destruction (4). Diabetes is transferable
from NOD mice by CD4+ T cells that express Th1
cytokines, while treatments with rIL-4 or rIL-10 have
been shown to protect them from diabetes (5). Like
NOD mice, a Th1-dominated infiltration of T cells into
the islets (insulitis) has also been observed in type 1
diabetic patients (6), suggesting that they too have an
underlying Th1 bias (3, 7). However, the respective con-
tributions of Th1 and Th2 cytokines to the pathogen-
esis of IMD remain controversial, with reports showing
that diabetes development in NOD mice may not
require IFN-γ signaling (8, 9) and can be accelerated by
the transgenic expression of IL-10 in pancreatic β cells
(10). In humans, Halminen et al. (11) recently studied
the expression profile of mRNAs of IFN-γ and IL-4 in
resting blood and found them both to be significantly
reduced in newly diagnosed diabetic patients as com-
pared with normal controls.
Both central and peripheral tolerance mechanisms
may be compromised in newly diagnosed IMD patients
and NOD mice. Clonal deletion of autoreactive T cells
in the thymus is one mechanism for the induction of
tolerance to self-antigens. This may involve diminished
expression of insulin in the thymus of individuals with
the protective genomic VNTR alleles 5′ to the insulin
gene. Others have suggested that it is the ineffective
antigenic binding to IMD-prone HLA-DQ or -DR that
promotes islet cell autoimmunity, since this permits
autoreactive T cells to escape thymic ablation and pass
into the circulation.
However, defective apoptosis of activated T cells have
been reported in animal models of diabetes (12) and
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Susceptibility to immune-mediated diabetes (IMD) in humans and NOD mice involves their inher-
ently defective T cell immunoregulatory abilities. We have followed  natural killer (NK) T cell num-
bers in patients with IMD, both by flow cytometry using mAbs to the characteristic junctions found
in the T cell receptors of this cell subtype, and by semiquantitative RT-PCR for the corresponding
transcripts.  Both before and after clinical onset, the representation of these cells in patients’ PBMCs
is reduced. We also report low numbers of resting CD4+ CD25+ T cells in IMD patients, a subset of 
T cells shown to have important immunoregulatory functions in abrogating autoimmunities in 
3-day thymectomized experimental mice. Whereas a biased Th1 to Th2 cytokine profile has been sug-
gested to underlie the pathogenesis of IMD in both species, we found defective production of IFN-γ
in our patients after in vitro stimulation of their PBMCs by phorbol-myristate acetate and ionomycin
and both IFN-γ and IL-4 deficiencies in Vα24+ NK T–enriched cells. These data suggest that multiple
immunoregulatory T (Treg) cell defects underlie islet cell autoimmunity leading to IMD in humans
and that these lesions may be part of a broad T cell defect.
J. Clin. Invest. 109:131–140 (2002). DOI:10.1172/JCI200213605.
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associations with CTLA-4 polymorphisms in type 1 dia-
betic patients, especially of Spanish descent (13), are two
observations that could explain breaches in peripheral
tolerance. T regulatory (Treg) cells are involved in almost
all experimental animal models of autoimmunity, and
natural killer (NK) T cells and resting CD4+CD25+ T cells
have emerged as important immunoregulatory T cell
subsets. Importantly, reconstitution of animal models
by populations of Treg cells has been shown to prevent
the development of autoimmunity.
Whereas NK T cells have powerful antitumor effects,
mediating their cytotoxicity by an NK-like effector mech-
anism that is IL-12 dependent (14, 15), they also serve as
regulators that secrete IL-4 and IL-13, and pro-Th2 fac-
tors that inhibit Th1-mediated cytotoxic T lymphocyte
(CTL) responses (16). NK T cells are either CD4+ (17) or
CD4–CD8– double negative (DN) (18) and have a highly
conserved TCR repertoire (19, 20). They are CD1d
responsive to antigen presented to them by dendritic
cells (DCs), but are not HLA restricted. The CD1d bind-
ing cleft is hydrophobic, binding and presenting glycol-
ipid rather than peptide antigens to responding NK T
cells. They express an invariant TCR α chain composed
of variable gene repertoire Vα14 and Jα281 segments in
mice or Vα24 and JαQ segments in humans, indicating
a highly conserved antigenic specificity, albeit their nat-
ural ligand has not yet been identified. These subsets are
also highly biased toward Vβ8.2, Vβ7, and Vβ2 usage in
mice and Vβ11 in humans. Both CD4+ and DN NK T
cell subsets produce high levels of IFN-γ and IL-4 when
stimulated (21). Disturbances in numbers and functions
of NK T cells have been implicated in several organ-spe-
cific animal models of autoimmunity as well as in
humans, although in some of these studies it is unclear
whether the changes reflect a cause or effect of disease.
Mieza et al. showed that murine Vα14+ T cells were
specifically reduced with aging in C57BL/6 lpr/lpr or
MRL lpr/lpr mice, whereas no age-related changes were
observed in control mice (22). Mice prone to experimen-
tal allergic encephalomyelitis, a T cell–mediated autoim-
mune disease like IMD, have serious functional defects
of NK T cells (23). Various studies in NOD mice have
suggested that these mice are deficient and/or function-
ally defective in NK T cells and that diabetes can be pre-
vented by adoptive transfer of NK T cell–enriched DN
cells (24–26). Similarly, human studies have suggested
that NK T cell deficiencies are associated with various T
cell–mediated autoimmune diseases (27–29).
NK T cells with their invariant TCR are not the only
population of Treg cells, since T cells with diverse
TCRs expand in autologous mixed lymphocytic reac-
tions and mediate antigen-specific suppressor activi-
ty. CD4+CD25+ T cells are a unique population of Treg
cells in that when otherwise normal mice made defi-
cient by 3-day thymectomies, they develop organ-spe-
cific autoimmunities, which are preventable by trans-
fer of CD4+/CD25+ T cells (30). CD4+CD25+ T cells in
normal mice thus represent a distinct lineage of “pro-
fessional” suppressor cells (31) thought to act through
direct contact with responder cells rather than
through released cytokines (32). Previous studies have
shown that prior elimination of this CD4+ T cell sub-
set from splenocytes by Ab’s to CD25 (5–10% of
peripheral CD4+ T cells) makes these cells potent
inducers of autoimmunity when injected into nude
mice (33). However, little information was available on
this subpopulation in humans until recently. Stephens
et al. (34) showed that this subset of Treg cells in
human thymus and periphery mediates immunoregu-
latory effects through direct cell contacts. These
human cells behave very similarly to those described in
mice by expressing CTLA-4 constitutively, by becom-
ing anergic in the absence of exogenous IL-2, and by
suppressing the activation of CD4+CD25– cells in
vitro. As a consequence, we studied the CD4+/CD25+
subset as well as NK T cells in IMD patients to explore
their possible roles in the disease.
Here we report that in spontaneous IMD of humans,
regulatory/suppressor T (Treg) cells are markedly
reduced in numbers, and peripheral T cells are defec-
tive in secreting Th1 (IFN-γ) cytokine, suggesting some
broad underlying intrinsic T cell defects of which defec-
tive Treg cells (NK T and CD4+CD25+ T cells) are a part.
Methods
Patients. All 54 type 1 diabetic study patients fulfilled
the diagnostic criteria in that they presented with sus-
tained hyperglycemia, proneness to develop ketoacido-
sis, polyuria, polydipsia, weight loss, and symptoms
consistent with underlying insulinopenia. The diagno-
sis of IMD was confirmed by the presence of cytoplas-
mic islet cell autoantibodies (ICA), and/or autoanti-
bodies to glutamic acid decarboxylase (GAD65A),
and/or to the tyrosine phosphatase insulinoma anti-
gen-2 (IA-2A), and/or to insulin (IAA). Blood samples
were collected from 31 newly diagnosed diabetic
patients within 3 months of their diagnosis and from
23 long-established patients who have had diabetes for
8.7 ± 7.0 years. We studied 12 nondiabetic relatives of
such patients who were at risk of impending diabetes
because they had one or more positive ICAs. We also
studied 15 type 2 diabetic patients as diabetic controls.
These latter patients had strong family histories of type
2 diabetes, were overweight (body mass indices greater
than 27), and all but one had acanthosis nigricans.
Blood samples were also obtained from 26 normo-
glycemic volunteer controls under protocols approved
by Weill/Cornell-New York Hospital institutional
review board (Table 1). Fresh PBMCs were isolated on
Ficoll density gradients and analyzed within hours of
sampling in all cases.
Ab’s and reagents. The following Ab’s from Coulter
Immunotech (Miami, Florida, USA) were used in our
studies: IgG1 (679.1Mc7), IgG2a (U7.27), anti-Vα24
(C15), anti-Vβ11 (C21), and anti-human CD25
(B1.49.9). Anti-CD3 (UCHT-1), anti-CD4 (Q4120), and
anti-CD8 (UCHT-4) were purchased from Sigma Chem-
ical Co. (St. Louis, Missouri, USA). Ab’s to the cytokines
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IFN-γ and IL-4 were purchased from PharMingen (San
Diego, California, USA). The mAb (6B11) to the invari-
ant Vα24JαQ junction used in our studies was devel-
oped by B. Wilson and M. Exley as follows.
Briefly, cyclic peptides representing the CDR3 loop of
the invariant TCR-α sequence acetylCVVSDRGTLGR-
LADCG with C at P15 were linked to the acetyl methyl-
ene group by a thioether linkage. This construct left the
sulfhydryl of the C residue available for coupling to 
N-ethylmaleimide–activated keyhole limpet hemocyanin
(KLH), BSA, or ovalbumin. The cyclic peptide was cou-
pled to activated KLH for immunization, to BSA to
boost the response, and to ovalbumin to screen hybrido-
mas, as recommended by the manufacturer (Pierce
Chemical Co., Rockford, Illinois, USA). One hundred
and twenty-nine C57BL/6 F2 CD1d knockout (KO) mice
(35) were immunized intraperitoneally and subcuta-
neously with invariant peptide-KLH and CFA, boosted
4 weeks later with invariant peptide-BSA and IFA, and
reboosted intravenously 10 days later, 4–5 days prior to
hybridoma fusion, with either invariant peptide-BSA or
a DN2.D6 invariant NK T cell clone (18). Following
fusion with NS0 myeloma by conventional means, each
hybridoma was screened by ELISA on invariant peptide-
ovalbumin, and those determined to be positive were
counter-screened against ovalbumin alone.
Hybridomas secreting Ab’s reactive with invariant
peptide were screened for reactivity against the
DN2.D625 and other invariant NK T cell clones and
for reactivity against control unrelated T cell clones by
indirect FACS using anti-IgG FITC as described (18).
Briefly, 106 cells were suspended in FACS buffer (PBS,
FBS 1%, and NaN3 0.1%) in a 96-well plate. Nonspecif-
ic binding was blocked by preincubating with 10%
human serum for 15 minutes. Ab’s were added to cell
suspensions for 20 minutes. Cells were then washed
with FACS buffer, incubated with anti–murine
immunoglobulin (anti-mIg), FITC (Pierce Chemical
Co.), rewashed, and analyzed by FACScan (Becton
Dickinson Immunocytometry Systems, San Diego, Cal-
ifornia, USA), using CellQuest Software.
Ab’s specifically reactive with invariant NK T cell clones
were tested for reactivity against PBMCs and polyclonal
invariant NK T cell lines. Two mAb’s in particular were
carried further since they clearly reacted specifically with
all invariant NK T cells tested. These were 6B11 (IgG1)
and 3A6 (IgM). The former mAb was used in our studies.
Phenotypic and functional analysis of human T cells.
Peripheral blood lymphocytes were analyzed by flow
cytometery using a FACScalibur (Becton Dickinson
Immunocytometry Systems). Immunofluorescence
staining was performed using specific mAbs according
to standard procedures. For enumeration of NK T cells,
at least 200,000 events were analyzed. Cytokine pro-
duction (IFN-γ and IL-4) was assessed by flow cytome-
try on phorbol myristate acetate and calcium iono-
mycin–activated (PMA + I–activated) cells. PBMCs
(106/well) were stimulated in 96-well round-bottom
plates for 5 hours with PMA (Sigma Chemical Co) at 50
ng/ml and I (Sigma Chemical Co.) at 1-µM concentra-
tions. Detection of intracellular cytokines was opti-
mized, by activating the cells in the presence of 3 µM
monensin (PharMingen), which prevents cytokine
secretion and thus allows their intracytoplasmic accu-
mulation. Unstimulated control wells were incubated
with monensin alone. Cells were fixed with 4%
paraformaldehyde at the end of a 5-hour incubation
period and were permeabilized with Perm/Wash solu-
tion containing saponin (PharMingen) to allow Ab
access for staining of IFN-γ and IL-4.
Isolation of CD4–CD8– DN T cells. T cells were separated
from PBMCs using a pan-T cell isolation kit (Miltenyi
Biotec, Auburn, California, USA). DN T cells were
obtained from PBMCs by negative selection using
CD4+ and CD8+ microbeads (Miltenyi Biotech).
Molecular analysis of canonical Vα24JαQ transcripts. A
Southern blot technique was used to identify the
Vα24JαQ TCR chain among the PCR-amplified 
Vα24-Cα clonotypes. Total RNA was extracted from
PBMCs and DN T cells using Trizol (Invitrogen, Carls-
bad, California, USA), and 2 µg was reverse transcribed
using an outer primer of the constant region of the
TCR-α (5′ ATACACATCAGAATTCTTACTTTG 3′) and of
the HPRT gene (5′ AGGGAACTGCTGACAAAGATTC 3′).
First-round RT-PCR was performed on the transcribed
cDNA using an outer primer of the variable region of
the canonical TCR Vα24 (5′ TATACAGCAACTCTG-
GAT 3′) in a thermal cycler GeneAmp PCR System
9700 for 30 cycles (60 seconds at 94°C, 60 seconds at
50°C, and 60 seconds at 72°C). The second round of
PCR was performed using the inner primer pair (sense
5′ AAGCAAAGCTCTCTGCACATCACA 3′ and antisense 
5′ GTCACTGGATTTAGAGTCT 3′) under the conditions
identical to those of the first round of PCR. The sam-
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Table 1
Patients demographics
Groups Total number of subjects Male/female Mean age (years) ± SD ICA+/ICA– GAD65AA IA-2AB
Normal controls 26 12/14 37 ± 5.66 0/25 0/25 0/25
ICA+ relatives 12 5/7 15.82 ± 11.44 12/0 7/12 5/12
Newly diagnosed type 1 diabetics 31 17/14 9.4 ± 2.16 28/3 8/31 13/31
Long-standing type 1 diabetics 23 12/11 45.2 ± 9.7 14/9 8/23 4/23
(Duration 8.7 + 7.0 years)
Type 2 diabetics 15 2/13 35.35 ± 19.63 0/14 0/14 0/14
AGlutamic acid decarboxylase autoantibodies. BInsulinoma-associated tyrosine phosphatase-like protein-2 autoantibodies.
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ples were then loaded onto a 2% agarose gel. After elec-
trophoresis, the DNA was transferred to a nylon mem-
brane (Hybond–N) and was hybridized with [γ-32P]
ATP-labeled JαQ probe (5′ ACTCAGTTGACTGTCTGGC-
CTGAT 3′). The filter was prehybridized at 65°C
overnight in buffer followed by overnight hybridiza-
tion at 50°C in the presence of 32P-labeled JαQ probe.
The membrane was later washed in 2×, 1×, and 0.5×
SSC for 20 minutes at 55°C and was subsequently
autoradiographed. The PCR products were quantified
using phosphorimaging.
Similarly, PCR was performed using HPRT primers
(sense 5′ GTCGTGATTAGTGATGATGAAACCAGGTTAT-
GACC 3′ and antisense 5′ CACCAGCAAGCTTGCGAC-
CTTG 3′), and the PCR product (474 bp) was hybridized
with [γ-32P] ATP-labeled HPRT probe (5′ GCCATCA-
CATTGTAGCCCTCTG 3′).
CD1d sequencing. The human CD1d gene mutation
study was carried out using an ABI 377 automatic
sequencer. Primer pairs covering the whole CD1d gene
were designed based on the sequence of CD1d gene
(accession number X14974). Genomic DNA (10 ng) from
both patients and normal controls used as a template was
amplified by appropriate primer pairs using Taq DNA
polymerase in a 50-µl reaction volume under standard
reaction conditions. The PCR products were precipitat-
ed twice by isopropanol/ethanol and dissolved in 25 µl
H2O. Two microliters of the dissolved PCR products were
then used as a template DNA for each sequencing reac-
tion following the applied biosystems inherit protocol.
Sequence data of each patient and normal control was
compared with the reference sequence of CD1d in the
gene bank (GenBank National Center for the National
Library of Medicine Biotechnical Information, NIH,
Bethesda, Maryland, USA) by Sequencer software.
All six exons of CD1d gene were PCR amplified using
primers that flanked each exon as shown below:
exon 1: forward primer GAATTGGCTGGCACCCAGCG-
GAAAG, reverse primer CGAGTTTTCTACCTAGATCGCG;
exon 2: forward primer CCACTTGCTACACGCCTCCAATC,
reverse primer CCAGTTGAGTTTCTGTGGCCATTC; exon
3: forward primer CTCAAATGTCCCTCGTTCCTGC,
reverse primer GCTCAAAGGGATGAGAACCCTGG; exon 4:
forward primer CCAGAAGTGAACATGTCAGG, reverse
primer CCTCCTGCCATTTCCAGCTTGG; exon 5 and 6:
forward primer GTACCCTCACACATGCCTAGAC, reverse
primer CTTGGGAACCTGAGGTCCAGAG.
In addition, the 1.8-kb upstream regulatory region of
CD1d gene was also screened for mutations by PCR-
based sequencing analysis. We designed three sets of
primer pairs, test, t, each covering an interval of around
600 bases in this region.
Promoter region 1: forward primer GATAGGC-
TGGGTTAGGGCTG, reverse primer CAAGATTAT-
GCGCCCTCTAGC; promoter region 2: forward primer
GATGCTGGGGTGTGAGGTGATG, reverse primer CTG-
GATTAGGTTGGCTAC; promoter region 3: forward
primer GAATCCTGGGATATGACAGTTG, reverse primer
CTCTGACCTGCGCACTCTTCT.
Statistical analysis. Differences between mean values
were evaluated by two-sided Student t test, with a level
of significance set as P values less than 0.05.
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Figure 1
NK T cell defect in IMD patients. (a) NK T cells in the
peripheral blood were characterized by a three-color flow
cytometry assay using mAbs to CD3 and to receptors bear-
ing expressed Vα24 and Vβ11. The triple-positive popula-
tion (CD3+Vα24+Vβ11+) showed marked reductions in
both newly diagnosed (P < 0.0001) and long-term
immune-mediated diabetic patients (P < 0.007) compared
with controls. Nine multi-autoantibody–positive relatives
of the 12 patients studied similarly had significantly
reduced numbers of triple-positive cells (P < 0.0001).
Whereas the type 2 diabetic patients also had lower levels
than controls (P < 0.02), their deficiency was less marked
than the IMD patients (P < 0.04). The horizontal lines rep-
resent means; n is the number of subjects in each group.
(b) Comparisons are shown between NK T cells as defined
by staining with CD3, Vα24, and mAb to the Vα24JαQ
junction (6B11) to NK T cells defined by staining with
CD3+Vα24+Vα11+ mAbs in patient and control groups. No
differences were found in the NK T cell numbers as stained
by the two different sets of mAbs. (c) A dot plot compar-
ing the measurement of NK T cells using Vα24 and Vβ11
mAbs and Vα24 and the invariant JαQ junction mAb
(6B11) in a representative normal control and a newly
diagnosed IMD patient are shown. The patient has
reduced doubly stained cells (upper-right quadrants) using
either sets of mAbs. *P < 0.007, **P < 0.04.
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Results
Phenotypic and molecular characterization of NK T cells in the
peripheral blood of patients with IMD. All 31 newly diag-
nosed IMD (28 were ICA+) and 14 of the 23 long-stand-
ing type 1 diabetic patients were positive for one or
more islet autoantibodies when studied. Conversely,
none of the 26 controls or the 15 type 2 diabetic
patients had any ICAs. Detailed patient demographics
and autoantibodies identified, including the 12 Ab-
positive but nondiabetic persons, are shown in Table 1.
NK T cells represent only approximately 1% of the nor-
mal PBMC population. Cell surface phenotype analyses
of PBMCs using mAbs to encompass the human NK 
T cell subset (CD3+, Vα24+, and Vβ11+ TCR) in a three-
color assay clearly showed a reduction in the number of
such cells in newly diagnosed IMD patients compared
with normal controls (Figure 1a). Reduced numbers of
NK T cells (<0.1% of Vα24/Vβ11+ T cells) were also evi-
dent in 9 of the 12 autoantibody-positive but nondia-
betic patients, and in 17 of the 23 long-diagnosed IMD
patients. Whereas the type 2 diabetic patients (n = 15)
had reduced numbers of NK T cells over those of normal
controls (P < 0.02), the number was significantly more
than the newly diagnosed IMD patients (P < 0.04). The
26 normal controls had a mean percentage of
CD3+Vα24+ T cells of 0.74% ± 0.06%, whereas that of
CD3+Vβ11+ T cells was 0.94% ± 0.09%. The mean per-
centage of CD3+Vα24+ in newly diagnosed IMD patients
(n = 31) was lower at 0.38% ± 0.02% (P < 0.0001). Simi-
larly, CD3+Vβ11+ T cells were reduced in new-onset IMD
at 0.44% ± 0.02% (P < 0.0001). These T cell numbers were
also significantly lower in the long-standing IMD
patients, 0.34% ± 0.02% (P < 0.0001) and 0.53% ± 0.03%
(P < 0.001) for CD3+Vα24+ and CD3+Vβ11+ cells, respec-
tively. Nine of the 12 ICA+ relatives with additional Ab’s
(four GAD65A+, two IA-2A+, and three GAD65A+ plus 
IA-2A+) showed significantly reduced CD3+Vα24+ cells
(0.53 ± 0.2, P < 0.02) when the other three (with normal
values) were excluded. This was significant in that all
nine of these relatives were at high risk for diabetes
themselves, whereas the other three with only one
autoantibody had a much lower risk (36). However the
entire group of 12 relatives had low numbers of
CD3+Vβ11+ cells (0.59 ± 0.05, P < 0.03).
To exclude that we were measuring significant num-
bers of conventional T cells that happened to express
Vα24+ and/or Vβ11+ TCR, we confirmed our data by
using mAb (6B11) to the invariant Vα24JαQ junction
and found nearly identical results (Figure 1, b and c),
documenting that the triple-positive T cells (Figure 1a)
were essentially all NK T cells.
As an additional confirmation, we next examined
CD4–CD8– DN populations obtained from PBMCs
from normal controls, IMD, and type 2 diabetic patients
for their expressions of the canonical TCR (Vα24JαQ)
segment using RT-PCR. After PCR amplification with a
set of the Vα24 and Cα primers, the PCR products were
separated by electrophoresis on 2% agarose gel, and spe-
cific bands of approximately 190 bp were detected. The
PCR products were blotted onto nylon membranes and
were hybridized with [γ-32P] ATP-labeled oligonu-
cleotide probe specific for JαQ. Both normal controls
and the IMD patients expressed Vα24JαQ, but the
mean level of expression in the patients was reduced
approximately fivefold compared with the normal con-
trols (Figure 2a), as determined by quantitative phos-
phorimaging (P < 0.01) (Figure 2e). While the type -2
diabetic patients had lower mean levels of expression of
the canonical transcript in the PBMCs as compared
with the normal controls (P < 0.05), the expression 
was significantly more than type 1 diabetic patients 
(P < 0.05) (Figure 2c). In total, four controls (all normal)
and four type 2 diabetic patients (intermediate expres-
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Figure 2
PBMC and CD4–CD8– DN T cells from patients and normal controls
were examined for Vα24JαQ expression by the Southern blot tech-
nique. (a and c) Vα24JαQ TCR transcripts are shown. (b and d) For
the housekeeping gene HPRT expressions in the same subjects. (a)
Expression of Vα24JαQ mRNA in the peripheral blood of IMD
patients (lanes 1, 2, 4, 5, 6, 9, 10, and 11) are compared with nor-
mal controls (lanes 3 and 12). Lanes 7 and 8 compare the TCR
expression in the DN population between controls and patients,
respectively. Lane 13 is the negative control. (c) This figure part
compares the expression of canonical Vα24JαQ transcripts in the
patients with type 2 diabetes (lanes 1, 2, and 3) with a normal con-
trol (lane 4). Lane 5 is the negative control. The arrows indicate the
position of the invariant Vα24JαQ and HPRT bands. (e) The rela-
tive expression intensities of the canonical Vα24JαQ TCR as nor-
malized to HPRT gene expression in controls, IMD patients, and
patients with type 2 diabetes are shown. The mRNA levels were all
determined by RT-PCR followed by quantification of radiolabel by
phosphorimaging. Shown in e are the mean levels of Vα24JαQ cal-
ibrated to the amount of HPRT gene expression in the sample. The
bars indicate means plus 1 SE. Significant differences from the nor-
mal control group are *P < 0.05 and ** P < 0.01.
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sion), plus 15 patients with IMD (all abnormal) were
studied. Furthermore, by sequencing the PCR products
eluted from the gel, we confirmed that these bands cor-
responded to the invariant Vα24JαQ TCR, a marker for
human NK T cells.
Functional (cytokine) abnormalities of patient Vα24+ T
cells. We found that NK T cells in normal controls rep-
resented approximately one-half of all the CD3+Vα24+
T cells in that they expressed Vβ11 as well as the canon-
ical Vα24JαQ junction. We studied the Vα24+ subpop-
ulation of T cells as highly enriched for NK T cells for
their INF-γ and IL-4 cytokine expressions in the various
patient groups by a three-color FACS assay and found
that while the numbers of IFN-γ were always more than
IL-4–secreting cells, the number secreting either IFN-γ
or IL-4 cytokines was reduced in both newly diagnosed
and long-standing IMD patients, compared with the
normal controls (Table 2). Similarly, the ICA-positive
but nondiabetic relatives showed reduced IFN-γ secre-
tion as compared with the normal controls.
Lack of association of CD1d with human IMD. Since
defective CD1d signaling could lead to defective NK
T cell stimulation, we next compared CD1d gene
structure in ten diabetic patients and ten controls.
We found no mutations or polymorphisms using
automated sequencing within the coding region of
CD1d gene. While both homozygous and heterozy-
gous substitutions were found at four different posi-
tions in the sequences, in the 5′ UTR located in the
region of 600–800 base, upstream of the start code of
the CD1d gene, they randomly occurred in both the
patients and controls, implying that these four sub-
stitutions are irrelevant polymorphisms and not dis-
ease-significant mutations. Thus we found no genet-
ic evidence for an association of the CD1d gene in the
pathogenesis of IMD.
Deficiency of immunoregulatory CD4+CD25+ T cells in
patients with IMD. We next tested resting CD4+ T cell
expression of CD25 (IL-2R-α) in our patients with type
1 diabetes. Significant deficiencies of these regulatory
T cells were regularly seen in our patients but not in the
type 2 diabetics or in the normal controls (Figure 3).
However, no differences were found in the expression
of CD122 (IL-2R-β) on the resting T cells between
patients and controls. This data confirms that this
unique regulatory T cell subset is also deficient in IMD
patients as in NOD mice (37). We studied two ICA+ rel-
atives (one GAD65A+ plus IA-2A+ and one GAD65A+),
and these relatives also had reduced CD4+CD25+ T cells
(mean 3.21 ± 0.53) as compared with the normal con-
trols (P < 0.001).
Intrinsic cytokine defect in IMD patient T cells. NOD
mice have been reported to have T cell abnormalities,
as have diabetic patients, particularly in their hetero-
geneous T cell cytokine responses to different stimuli.
We studied the cytokine responses of patient T cells
after their stimulation with PMA + I. PMA acts by acti-
vating protein kinase C directly while I causes an
influx of Ca2+ from the extracellular space into cell
cytoplasm. The FACS analysis was carried out in CD3+
T cells from 16 newly diagnosed IMD patients, and
the cytokine expressed (IFN-γ) was significantly
reduced when compared with 21 normal controls
studied identically. The number of CD3+ T cells
secreting IL-4 was not different when we excluded the
two normal control outliers that showed high IL-4
production (Figure 4, a and b), however the numbers
of CD3+ T cells secreting IFN-γ were reduced in long-
standing IMD patients, while it was the CD4+ T cells
that were defective in secreting these cytokines (Fig-
ure 4, b and c). Seven autoantibody-positive nondia-
betic subjects were also studied for cytokine expres-
sion of their CD3+ T lymphocytes after PMA + I
stimulation, and three ICA+ subjects showed reduced
IFN-γ (P < 0.01) and IL-4 (P < 0.03) like the newly diag-
nosed IMD patients, and two of these three patients
were at high risk of impending IMD because of posi-
tive GAD65A plus IA-2A (36). The remaining autoan-
tibody-positive subjects (four of seven) showed nor-
mal numbers of T cells secreting IFN-γ.
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Figure 3
Deficiency of CD4+CD25+ T cells in IMD patients. Resting PBMCs
were stained with mAbs to CD4 and CD25 in a two-color flow
cytometry assay and analyzed by flow cytometry. In newly diagnosed
IMD as well as long-standing type 1 diabetic patients, the mean per-
centage of these immunoregulatory cells of CD4+ T cells was reduced
to 2.6 ± 0.23 (P < 0.001) and 3.7 ± 0.69 (P < 0.002), respectively,
with 6.9 ± 0.4 and 6.3 ± 0.48 (P = NS) in the normal control and type
2 diabetic groups, respectively. The horizontal line represents the
mean of that group.
Table 2
Functional defect of peripheral CD3+Vα24+ cells in IMD patients 
Groups IFN-γ IL-4 
(% mean + 1 SEM) (% mean ± 1 SEM)
Normal controls (n = 5) 0.794 ± 0.17 0.118 ± 0.02
ICA + relatives (n = 5) 0.224 + 0.05A 0.082 + 0.02
Newly diagnosed diabetics (n = 6) 0.194 ± 0.05A 0.04 ± 0.01A
Long-standing diabetics (n = 10) 0.282 ± 0.04A 0.028 ± 0.006A
PBMCs of the patients and normal controls were stimulated with PMA + I
and stained for cell surface antigens (CD3 and Vα24) and both Th1 
(IFN-γ) and Th2 (IL-4) intracellular cytokines. CD3+ T cells were gated and
analyzed for the expression of Vα24 (to enrich for NK T cells) and IFN-γ or
IL-4. CD3+Vα24+ T cells were significantly defective in secretion of either
IFN-γ or IL-4 both in newly diagnosed (P < 0.02 and 0.04) as well as long-
diagnosed IMD patients (P < 0.03 and 0.01) as compared with the con-
trols. AStatistically significant.
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Discussion
We have identified defects in peripheral Treg cells in
IMD patients affecting both the NK T and CD4+/CD25+
T cell subsets and a functional abnormality of periph-
eral blood T cells manifested by diminished production
of Th1 (IFN-γ) cytokine after their in vitro stimulation
with PMA + I. All of these abnormalities could be the
result of an underlying thymic disorder. While some
type 2 diabetic patients also have low levels of NK T
cells, but not to the degree found in IMD, their
CD4+CD25+ T cell numbers, however, are normal.
Clonal deletion or anergy of autoreactive T cells is
an important mechanism to obviate autoimmunities,
however peripheral T cell subsets actively contribute
to the maintenance of self-tolerance. We found low
numbers of NK T cells in prediabetic, newly diag-
nosed, and long-standing IMD patients alike using
extensive flow cytometry methods as verified through
RT-PCR analyses. A previous study reported reduced
JαQ+ TCR transcripts in T cell clones produced from
purified DN T cells that expressed Vα24+ TCR in type
1 diabetic and nondiabetic siblings of IMD patients
(nine patients vs. six normal controls) (38). We found
two JαQ hybridizing transcript bands in our RT-PCR
studies that likely represent the invariant Vα24JαQ
segment with an alternative sequence (39). We
sequenced the lower band from normal controls and
found it to correspond to the canonical Vα24JαQ, but
could not obtain sufficient PCR product from the
IMD patients for sequencing. In line with our data of
reduced numbers of NK T cells in IMD presented
herein, similar observations have been made in
patients with other autoimmune diseases such as sys-
temic sclerosis (27), multiple sclerosis (29), and
rheumatoid arthritis (28), suggesting that this defi-
ciency predisposes to autoimmunity beyond that
restricted to pancreatic islet cells as in IMD. We also
found that NK T cells in IMD had functional defects
in their abilities to produce cytokines, especially 
IFN-γ. A previous report suggested that NK T cell
clones developed from patients with type 1 diabetes
secreted IFN-γ but not IL-4 (38), while NK T cell
clones from their identical twins and siblings who
were discordant for diabetes secreted IL-4 normally.
The implication was that the patients’ IL-4–deficient
NK T cells might not be able to initiate Th2 respons-
es, but rather only Th1 pathway responses to self by
default. Furthermore, it was reported that IL-4–null
cells from diabetic patients had significant differences
in their expressions of the Th2 cytokine genes includ-
ing IL-5 (40). Our findings are reminiscent of those in
NOD mice where impaired immunoregulation corre-
lated with defective NK T cell proliferation and
impaired differentiation toward IFN-γ secreting phe-
notype (26). While NK T cells secrete large amounts
of both IFN-γ and IL-4 (41), we found diminished lev-
els of both cytokines in NK T cells in IMD. The mech-
anism by which immunoregulation is mediated by
NK T cells is unknown, however they are thought to
respond by engagement of their invariant TCR to one
or more self glycolipids presented in the context of
DCs expressing CD1d (42). Furthermore, CD1d
recognition in the thymus, and probably the periph-
ery as well, is a critical signal for maturation of NK T
cells (43, 44). However, we found no primary defects
in the structural CD1 gene or its promotor in our
IMD patients, but only nondiabetes-associated poly-
morphisms in CD1d gene (45). Takahashi et al. previ-
ously studied the expression levels of CD1a in periph-
eral blood DCs of the ICA+ and newly diagnosed
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Figure 4
Defective Th1 cytokine production in IMD patients at various stages of the dis-
ease. PBMCs from various groups were stimulated with PMA + I and were ana-
lyzed for the cell surface expression of CD3 and intracellular IFN-γ and IL-4
cytokines. Each dot represents one subject. (a) This figure depicts IFN-γ produc-
tion in the patient groups. The percentage of T cells secreting IFN-γ was signifi-
cantly reduced in newly diagnosed (P < 0.001) and long-standing IMD patients
(P < 0.03) compared with the normal controls. CD3+ T cells were further charac-
terized into CD4+ (b) and CD8+ (c) subsets for the cytokine production. CD4+ T
cells showed significantly reduced IFN-γ production in both newly diagnosed 
(P < 0.003) and long-standing IMD patients (P < 0.005). Three out of seven ICA+
relatives so tested also had reduced numbers of T cells secreting IFN-γ (P < 0.01),
while the other four were in the normal range. (d) Percentage of IL-4–secreting T
cells was not reduced in IMD patient groups compared with controls. The hori-
zontal bars represent the mean of that group.
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diabetic patients (46) and found them reduced; how-
ever, only CD1d presents antigen to NK T cells.
Besides NK T cells, CD4+CD25+ T cells can prevent
the development of autoimmune diseases such as thy-
roiditis (47), gastritis (48), and diabetes (49) when
transferred into experimental animal models. We and
others have shown a reduction in this CD4+ subset in
NOD mice (37, 50). These resting CD4+CD25+ T cells
represent a unique subset of regulatory T cells with a
highly stable expression of IL-2Rα (CD25) in contrast
to the transient expression of CD25 seen on activated
T cells (31). Recently, the existence of CD4+CD25+ T
cells was described in human thymuses and peripher-
al blood (34, 51). These cells proliferate poorly to mito-
genic stimulation and suppress the proliferation of
CD4+CD25– T cells. Whereas we found the CD25+ sub-
set to be deficient in our patients, it remains to be
shown that such an immunoregulatory CD4+ T cell
population is a functionally and phenotypically homo-
geneous entity of Treg cells. However, the proportion
of these cells that expressed the apoptosis promoting
CTLA-4 antigen was similar in patients and controls
(data not shown).
While CD4+/CD25+ T cells were normal in type 2 dia-
betic patients, some had low numbers of NK T cells.
Various studies in genetically obese Wistar fatty rats and
obese diabetic mice (52, 53), as well as patients with type
2 diabetes (54), have been reported to have impaired
cell-mediated immune responses, explaining the
increased incidence of infections in these patients. The
metabolic glucose disturbance is the probable explana-
tion (55–57). Indeed, our patients in the best diabetes
control appeared to have normal numbers of NK T cells.
This is consistent with the suggestion of von Kanel et al.
(56) that hyperglycemia promotes lymphopenia. Many
of our type 2 diabetic patients with low levels of NK T
cells were also being treated with PPAR-γ agonists when
studied, agents that have been recently recognized to be
anti-inflammatory (58). It is therefore plausible that
these drugs could affect NK T cell levels too.
The role of cytokines in mediating autoimmune dia-
betes has been extensively studied in NOD mice.
Intraislet expression of IFN-γ is generally associated
with pathology, while IL-4 expression induced experi-
mentally usually blocks the development of the disease
(4, 59). This imbalance between Th1/Th2 pathways
might be a possible mechanism for the exacerbation of
the disease, albeit we believe this idea to be overly sim-
plistic. In fact we found no evidence for polarized Th1
over Th2 responses to the strong in vitro stimulus of
PMA + I. Reduced IL-4 as well as IFN-γ levels in the
mRNA expression profiles in the resting PBMCs of
newly diagnosed diabetic patients have been reported,
in line with our findings (11). Th1 cells are more prone
to activation-induced apoptosis than are Th2 cells.
Thus their deletion might occur preferentially and
spare β-cell autoreactive T cells producing Th2 rather
than Th1 cytokines. This could be misinterpreted as a
Th1 to Th2 deviation among β cell–infiltrating T cells
of NOD mice protected from overt diabetes by various
immunostimulatory treatments such as  bacillus,
camette, guerin, and CFA (60).
Our findings suggest that there is an underlying
global defect in T cells in IMD leading to immune defi-
ciencies affecting immunoregulation. Others have sug-
gested a global T cell defect in the disease, too (61). Low
T cell IL-2 production was reported in IMD patients
that appeared to be related to marked β cell destruction
(62). Another study found IL-2 and soluble IL-2 recep-
tor secretion defects in both newly diagnosed and long-
standing diabetic patients (63). Moreover, a defective
thymic T cell activation to ConA and anti-CD3 has
been observed in NOD mice, suggesting a T cell defect
in this animal model as well (64). This T cell hypore-
sponsiveness correlates with reduced p56lck that is
involved in the T cell signal transduction pathway as
suggested by Nervi et al. (65). Further studies are
required to quantify the molecules involved in the T
cell signal-transduction pathways in these patients.
In conclusion, we postulate that the dual reductions
of peripheral NK T cells and CD4+CD25+ T cells rep-
resent major underlying defects in the T cell regulato-
ry network underlying IMD. We have found identical
defects in NOD mice (50) that are severely deficient in
NK T cells studied in several tissues by the expression
of the invariant Vα14Jα281 TCR transcripts by a
quantitative real-time RT-PCR. The dual immunoreg-
ulatory defect that we have exposed may be a reflection
of a broad T cell lesion. This could result from an
underlying defect in antigen-presenting cells (66, 67),
albeit a thymic disorder affecting their genesis is equal-
ly plausible. Since NK T cells were not absent in our
patients, ways to stimulate them should be actively
sought to provide novel therapies for the future. At
present, α-galactosylceramide (αGalCer) is such an
antigen with proven capability to do this, yet this sub-
stance is not a normal bodily constituent (only βGal-
Cer is found in mammalian tissues), while an inadver-
tent deviation toward a Th1 response through use of
this agent or its analogues could conceivably worsen
rather than help the underlying pathogenic process.
Very recent reports of αGalCer as a preventative in
NOD mice have been very encouraging (68, 69). Thus
the exciting possibility of a therapeutic benefit in
patients warrants that such avenues be actively pur-
sued in human trials under the appropriate safeguards
in the near future, while bone marrow reconstitutions
might come to have a therapeutic place as the risks
from the procedure continue to decline.
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